Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine

Seminars in Cancer Biology

Volumn 13, Issue 6, 2003, Pages 401-407

  Hsueh, Eddy C ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Canvaxin; Melanoma; Vaccine therapy

Indexed keywords

CANCER VACCINE; CANVAXIN; CANVAXIN THERAPEUTIC POLYVALENT CANCER VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS;

EID: 0742287072     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.003     Document Type: Article

References (43)

1. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today. 20:1999;158-160.
2. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S.et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U.S.A. 95:1998;1178-1183.
3. Hsueh E.C., Gupta R.K., Yee R., Leopoldo Z.C., Qi K., Morton D.L. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann. Surg. Oncol. 7:2000;232-238.
4. Triozzi P.L., Khurram R., Aldrich W.A., Walker M.J., Kim J.A., Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 89:2000;2646-2654.
5. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P.et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8:2002;1021-1032.
6. Hayashi Y., Hoon D.S., Park M.S., Terasaki P.I., Foshag L.J., Morton D.L. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell Immunol. 139:1992;411-425.
7. Overwijk W.W., Lee D.S., Surman D.R., Irvine K.R., Touloukian C.E., Chan C.C.et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 96:1999;2982-2987.
8. Dieckmann D., Plottner H., Berchtold S., Berger T., Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 193:2001;1303-1310.
9. Morse M.A., Clay T.M., Mosca P., Lyerly H.K. Immunoregulatory T cells in cancer immunotherapy. Exp. Opin. Biol. Ther. 2:2002;827-834.
10. Kirkwood J.M., Strawderman M.H., Ernstoff M.S.et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14:1996;7-17.
11. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K.et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17:1999;2105-2116.
12. Wang F., Bade E., Kuniyoshi C., Spears L., Jeffery G., Marty V.et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5:1999;2756-2765.
13. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V.et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 97:2003;186-200.
14. Morton D., Foshag L., Hoon D.et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:1992;463-482.
15. Berd D., Sato T., Mastrangelo M.J. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol. Immunother. 51:2002;320-326.
16. Sondak V.K., Liu P.Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A.et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20:2002;2058-2066.
17. Hersey P., Coates A.S., McCarthy W.H., Thompson J.F., Sillar R.W., McLeod R.et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 20:2002;4181-4190.
18. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. and Southwest Oncology Group. Adjuvant immunotherapy of resected intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75.
19. Bystryn J.C., Zeleniuch-Jacquotte A., Oratz R., Shapiro R.L., Harris M.N., Roses D.F. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. 7:2001;1882-1887.
20. Palmer K., Moore J., Everard M., Harris J.D., Rodgers S., Rees R.C.et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 10:1999;1261-1268.
21. Schreiber S., Kampgen E., Wagner E., Pirkhammer D., Trcka J., Korschan H.et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum. Gene Ther. 10:1999;983-993.
22. Moller P., Moller H., Sun Y., Dorbic T., Henz B.M., Wittig B.et al. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther. 7:2000;976-984.
23. Moller P., Sun Y., Dorbic T., Alijagic S., Makki A., Jurgovsky K.et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br. J. Cancer. 77:1998;1907-1916.
24. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C.et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13141-13146.
25. Kusumoto M., Umeda S., Ikubo A., Aoki Y., Tawfik O., Oben R.et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50:2001;373-381.
26. Maio M., Fonsatti E., Lamaj E., Altomonte M., Cattarossi I., Santantonio C.et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 51:2002;9-14.
27. Osanto S., Schiphorst P.P., Weijl N.I., Dijkstra N., Van Wees A., Brouwenstein N.et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11:2000;739-750.
28. Chang A.E., Li Q., Bishop D.K., Normolle D.P., Redman B.D., Nickoloff B.J. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 11:2000;839-850.
29. Kadison A.S., Morton D.L. Immunotherapy of malignant melanoma. Surg. Clin. N. Am. 83:2003;343-370.
30. Hsueh E.C., Nathanson L., Foshag L.J., Essner R., Nizze J.A., Stern S.L.et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer. 85:1999;2160-2169.
31. Morton D., Barth A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 46:1996;225-244.
32. Morton D.L., Hsueh E.C., Essner R., Foshag L.J., O'Day S.J., Bilchik A. et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg. 236:2002;438-448.
33. Jones R.C., Kelley M., Gupta R.K.et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann. Surg. Oncol. 3:1996;437-445.
34. Barth A., Hoon D., Foshag L.et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 54:1994;3342-3345.
35. Hsueh E., Gupta R., Qi K., Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16:1998;2913-2920.
36. Hsueh E.C., Essner R., Foshag L.J., Ollila D.W., Gammon G., O'Day S.J.et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20:2002;4549-4554.
37. Faries M.B., Morton D.L. Melanoma: is immunotherapy of benefit? Adv. Surg. 37:2003;139-169.
38. DiFronzo L., Gupta R., Essner R.et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J. Clin. Oncol. 20:2002;3242.
39. Chung M., Gupta R., Hsueh E.et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J. Clin. Oncol. 21:2003;313-319.
40. Morton D., Ollila D., Hsueh E.et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J. Clin. 49:1999;101-116.
41. Morton D., Eilber F., Malmgren R., Wood W. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 68:1970;158.
42. Hoon D., Bostick P., Kuo C.et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60:2000;2253-2257.
43. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J.et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.